Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,081 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vision Disorder Clear all
Recruiting Not applicable Interventional

Strategies for Improving Linkage-to-Care After Eye Disease Screening

NCT06943599
View directory record Official record
Conditions
Age Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions
Text Message Reminder, Health Worker Visit
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Completed No phase listed Observational

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

NCT03843593
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
Demographics Questionnaire, Adjuvant Treatment Beliefs Scale10, Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13, Decisional Regret14, Clinician Preference for Treatment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 30, 2026, 6:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis

NCT06495138
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
StableEyes
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

NCT00650338
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Artesia, California • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Oct 30, 2026, 6:07 AM EDT
Completed No phase listed Observational

Comparing the Effect of the Water Drinking Test on Intraocular Pressure

NCT02001155
View directory record Official record
Conditions
Glaucoma
Interventions
Water Drinking Test
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 30, 2026, 6:07 AM EDT
Not yet recruiting Not applicable Interventional

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

NCT07300852
View directory record Official record
Conditions
Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions
Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Ngoc Nguyen Inc.
Other
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 3 Interventional

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

NCT00051155
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 30, 2026, 6:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

An Early Prospective Study of the Traq™ Device for Characterization of Binocular Ocular Function in Normal Subjects and Subjects With Recent Traumatic Brain Injury

NCT07742878
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Concussion, Binocular Visual Function, Neuro-Ophthalmology, Saccadic Eye Movements
Interventions
Binocular ophthalmic neurodiagnostic device
Device
Lead sponsor
Rebiscan, Inc.
Industry
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Waukee, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension

NCT01520116
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3, Stage 1 - ATS907 - Dose 4, Stage 1 - Vehicle, Stage 2 - ATS907 - Dose A - to be selected based on Stage 1, Stage 2 - ATS907 - Dose B - to be selected based on Stage 1, Timoptic
Drug
Lead sponsor
Altheos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
Artesia, California • Glendale, California • Saint Joseph, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

NCT02507687
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty
Drug · Procedure
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
51
States / cities
Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 30, 2026, 6:07 AM EDT
Recruiting No phase listed Observational

The Effect of PROSE or Scleral Lenses on Mental Health

NCT07195721
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Boston Sight
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Completed No phase listed Observational

EX-PRESS® P-50 and EX-PRESS® P-200

NCT06119178
View directory record Official record
Conditions
Glaucoma
Interventions
EX-PRESS P-50 filtration device, EX-PRESS P-200 filtration device
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Rogers, Arkansas • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 30, 2026, 6:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

NCT07770685
View directory record Official record
Conditions
Glaucoma
Interventions
ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

NCT03931317
View directory record Official record
Conditions
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions
Latanoprostene bunod 0.024% QD, Timolol maleate 0.5% BID
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 30, 2026, 6:07 AM EDT
Not listed Phase 4 Interventional

The Effect of Education on Patient Compliance

NCT00376974
View directory record Official record
Conditions
Glaucoma
Interventions
American Academy of Ophthalmology Glaucoma Educational Tape
Behavioral
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2006 · Synced Oct 30, 2026, 6:07 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Autostereoscopic Dynamic Near Vision Testing

NCT04606355
View directory record Official record
Conditions
Visual Suppression, Amblyopia, Color Vision Defects
Interventions
Visual Acuity, stereopsis, Color vision
Diagnostic Test
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
1 Year to 95 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 4 Interventional Results available

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

NCT00140413
View directory record Official record
Conditions
Growth Hormone Deficiency, Septo-Optic Dysplasia, Hypopituitarism
Interventions
Nutropin AQ
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 5 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 30, 2026, 6:07 AM EDT
Not yet recruiting Phase 4 Interventional

Iopidine to Decrease Intraocular Pressure Rise After Injections

NCT07891910
View directory record Official record
Conditions
Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
Interventions
Apraclonidine 1.0% ophthalmic solution
Drug
Lead sponsor
Retina Consultants of Delmarva
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Easton, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Not applicable Interventional

Systane Ultra Versus Maxidex Versus Saline

NCT01775540
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Systane Ultra, Saline solution, Maxidex
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

NCT01276223
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 30, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

NCT03536559
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
Interventions
CNM-Au8, Placebo
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Not applicable Interventional

Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery

NCT01461291
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
iStent inject, Cataract surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
45 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 30, 2026, 6:07 AM EDT
Withdrawn No phase listed Observational

Definity for Ultrasound of Intraocular Tumors

NCT01930968
View directory record Official record
Conditions
Ocular Melanoma
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 4 Interventional

Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C

NCT00346489
View directory record Official record
Conditions
Glaucoma
Interventions
5-fluorouracil, Mitomycin C
Drug
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 30, 2026, 6:07 AM EDT